All lobbying filings
THE MCMANUS GROUP
THE MCMANUS GROUP filed a Q4 report for DENDREON PHARMACEUTICALS LLC on January 20, 2026, reporting $30,000 in lobbying income.
Lobbying for DENDREON PHARMACEUTICALS LLC · Biopharmaceutical company.
Filing · LD-2 quarterly report
Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$30,000
What the client paid this registrant for the period.
Client based in
California
Lobbyists on this filing
1
-
JOHN MCMANUSPreviously held: LA, Bill Thomas. Staff Director, W&M Health Subcommittee
Government bodies contacted
2
Lobbying activity
2
Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.
Issues related to the Department of Veterans Affairs National Oncology Program's Prostate Cancer Oncology Clinical Pathway.